terazosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 3584 63590-64-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terazosin
  • terazosin hydrochloride
  • terazosin hydrochloride anhydrous
  • terazosine
  • terazosin hydrochloride hydrate
  • terazosin HCl
induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
  • Molecular weight: 387.44
  • Formula: C19H25N5O4
  • CLOGP: 2.23
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 103.04
  • ALOGS: -2.41
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 24.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.86 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.98 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.038 Moderate 0.70
caco2-efflux Caco-2 efflux ratio (BA/AB) 30.832 Moderate 0.70
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 3.776 10^-6 cm/s Moderate 0.70
dh-clint Dog hepatocyte intrinsic clearance 0.834 uL/min/10^6 cells Moderate 0.70
dppb Dog plasma protein binding (% unbound) 58.880 % Moderate 0.70
fcs-ppb Fetal calf serum protein binding (% unbound) 81.600 % Moderate 0.70
herg hERG pIC50 4.655 pIC50 Moderate 0.70
hh-clint Human hepatocyte intrinsic clearance 1.052 uL/min/10^6 cells Moderate 0.70
hlm-clint Human liver microsomal intrinsic clearance 3.013 uL/min/mg protein Moderate 0.70
hppb Human plasma protein binding (% unbound) 33.590 % Moderate 0.70
kinase-safety-class ACVR2B,EIF2AK3,GRK2,MAPK7,PDK2,PDK4,PIK3CD,PRKDC 8
kinase-selectivity-class PRKDC,TTK 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 11.194 Moderate 0.70
mh-clint Mouse hepatocyte intrinsic clearance 9.036 Moderate 0.70
mppb Mouse plasma protein binding (% unbound) 59.880 Moderate 0.70
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 16.749 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.70
pppb Pig plasma protein binding (% unbound) 74.390 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 2.099 uL/min/10^6 cells Moderate 0.70
rh-fuinc Rat hepatocyte fraction unbound in incubation 81.150 % Moderate 0.70
rppb Rat plasma protein binding (% unbound) 57.430 % Moderate 0.70
solubility-dd Solubility at pH 7.4 in DMSO 749.894 uM Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
Aug. 7, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm skin 68.12 24.57 16 2409 3126 90622896
Vulvovaginal mycotic infection 61.62 24.57 17 2408 6297 90619725
Haemorrhoidal haemorrhage 59.74 24.57 16 2409 5307 90620715
Chest discomfort 49.80 24.57 36 2389 138329 90487693
Hypovolaemia 46.36 24.57 16 2409 12415 90613607
Hyperkalaemia 46.20 24.57 26 2399 64938 90561084
Blood pressure increased 34.79 24.57 34 2391 197183 90428839
Haemorrhoids 34.50 24.57 16 2409 26686 90599336
Clostridium difficile colitis 34.50 24.57 16 2409 26690 90599332
Cardiomegaly 33.02 24.57 14 2411 18911 90607111
Transplant dysfunction 32.75 24.57 10 2415 5272 90620750
Transient ischaemic attack 27.25 24.57 16 2409 43160 90582862
Iliac artery stenosis 26.04 24.57 4 2421 78 90625944
Dyspnoea 25.90 24.57 66 2359 880889 89745133
Forced expiratory flow decreased 24.62 24.57 4 2421 113 90625909

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 41.99 15.46 147 10142 257484 42353562
Dizziness 40.43 15.46 142 10147 249112 42361934
Syncope 38.08 15.46 78 10211 99328 42511718
Asthenia 35.67 15.46 148 10141 280645 42330401
Orthostatic hypotension 31.70 15.46 38 10251 30532 42580514
White coat hypertension 28.40 15.46 8 10281 346 42610700
Pulseless electrical activity 27.74 15.46 20 10269 8417 42602629
Blood alkaline phosphatase abnormal 27.71 15.46 9 10280 633 42610413
Heart valve incompetence 26.11 15.46 11 10278 1608 42609438
Myasthenic syndrome 25.54 15.46 9 10280 812 42610234
Distributive shock 24.51 15.46 12 10277 2484 42608562
Myocardial infarction 23.92 15.46 75 10214 123934 42487112
Bradyarrhythmia 23.72 15.46 12 10277 2663 42608383
Toxicity to various agents 23.58 15.46 13 10276 229123 42381923
Non-cardiogenic pulmonary oedema 20.77 15.46 8 10281 927 42610119
Dysuria 20.50 15.46 31 10258 31065 42579981
Chest pain 18.80 15.46 75 10214 139455 42471591
Presyncope 18.72 15.46 25 10264 22362 42588684
Diffuse alveolar damage 18.34 15.46 10 10279 2582 42608464
Prostatic disorder 17.55 15.46 11 10278 3678 42607368
Fall 16.59 15.46 105 10184 234415 42376631
Sopor 16.36 15.46 18 10271 13184 42597862
Sinus bradycardia 16.28 15.46 19 10270 14834 42596212
Coronary artery disease 15.85 15.46 38 10251 53682 42557364

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 67.96 15.36 159 11159 523690 110054291
Hyperkalaemia 60.48 15.36 72 11246 135724 110442257
Neoplasm skin 46.54 15.36 16 11302 3188 110574793
Acute kidney injury 42.42 15.36 152 11166 635278 109942703
Vulvovaginal mycotic infection 41.88 15.36 17 11301 5360 110572621
Myocardial infarction 38.67 15.36 70 11248 192013 110385968
Bradycardia 38.32 15.36 62 11256 155455 110422526
Orthostatic hypotension 37.82 15.36 40 11278 66209 110511772
Syncope 34.81 15.36 69 11249 202467 110375514
Dizziness 34.48 15.36 152 11166 698041 109879940
Coronary artery disease 33.54 15.36 39 11279 71651 110506330
Asthenia 33.26 15.36 149 11169 688850 109889131
Blood pressure increased 32.94 15.36 78 11240 258295 110319686
Haemorrhoidal haemorrhage 32.22 15.36 16 11302 8077 110569904
Pulseless electrical activity 30.86 15.36 20 11298 16737 110561244
Myasthenic syndrome 29.23 15.36 9 11309 1267 110576714
Chest pain 27.63 15.36 93 11225 376282 110201699
Prostatic disorder 26.88 15.36 10 11308 2499 110575482
Bradyarrhythmia 26.53 15.36 12 11306 4922 110573059
Heart valve incompetence 25.59 15.36 11 11307 3998 110573983
Cardiovascular disorder 25.35 15.36 20 11298 22740 110555241
Prostatomegaly 24.99 15.36 11 11307 4231 110573750
Chest discomfort 24.93 15.36 55 11263 173793 110404188
Distributive shock 24.47 15.36 12 11306 5892 110572089
Hypovolaemia 24.04 15.36 19 11299 21655 110556326
Cerebrovascular accident 23.38 15.36 55 11263 181229 110396752
Renal failure 23.23 15.36 63 11255 226511 110351470
Blood creatinine increased 23.06 15.36 55 11263 182834 110395147
Cardiomegaly 22.99 15.36 21 11297 29109 110548872
Diffuse alveolar damage 22.26 15.36 10 11308 4037 110573944
Dysuria 22.10 15.36 29 11289 60202 110517779
Presyncope 21.87 15.36 26 11292 48861 110529120
Non-cardiogenic pulmonary oedema 21.60 15.36 8 11310 1976 110576005
Blood alkaline phosphatase abnormal 20.95 15.36 7 11311 1280 110576701
Transient ischaemic attack 20.73 15.36 29 11289 63953 110514028
White coat hypertension 20.71 15.36 7 11311 1324 110576657
Atrial fibrillation 19.80 15.36 60 11258 229582 110348399
Dyspnoea 19.75 15.36 186 11132 1106686 109471295
Drug intolerance 18.87 15.36 9 11309 406503 110171478
Treatment failure 18.66 15.36 3 11315 277231 110300750
Alopecia 18.65 15.36 7 11311 364746 110213235
Cardiac failure congestive 18.59 15.36 45 11273 150955 110427026
Hepatic enzyme increased 18.46 15.36 5 11313 320887 110257094
Death 18.16 15.36 128 11190 698741 109879240
Transplant dysfunction 17.99 15.36 11 11307 8317 110569664
COVID-19 immunisation 17.05 15.36 6 11312 1280 110576701
Postoperative hypertension 16.95 15.36 3 11315 35 110577946
Gastrointestinal haemorrhage 16.93 15.36 46 11272 165472 110412509
Maternal exposure during pregnancy 16.62 15.36 3 11315 254880 110323101
Systemic lupus erythematosus 16.57 15.36 3 11315 254335 110323646
Iliac artery stenosis 16.57 15.36 4 11314 226 110577755
Hospitalisation 16.00 15.36 41 11277 142452 110435529
Sinus bradycardia 15.42 15.36 17 11301 29466 110548515
Forced expiratory flow decreased 15.38 15.36 4 11314 306 110577675

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA03 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:37890 ฮฑ-adrenergic antagonist
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:145947 antiatherosclerotic agent

Related Drugs by ATC class:

G04CA Alpha-adrenoreceptor antagonists 8 drugs
alfuzosindoxazosindutasteridefinasteridesilodosinsolifenacintadalafiltamsulosin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Cataract surgery contraindication 110473004
Syncope contraindication 271594007
Intraoperative floppy iris syndrome contraindication 418801006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.22 Basic
pKa2 0.72 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1MG BASE/ML TEZRULY NOVITIUM PHARMA N218139 July 29, 2024 DISCN SOLUTION ORAL 11224572 Feb. 1, 2041 TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN
EQ 1MG BASE/ML TEZRULY NOVITIUM PHARMA N218139 July 29, 2024 DISCN SOLUTION ORAL 11224572 Feb. 1, 2041 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN
EQ 1MG BASE/ML TEZRULY NOVITIUM PHARMA N218139 July 29, 2024 DISCN SOLUTION ORAL 12427108 Feb. 1, 2041 TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN
EQ 1MG BASE/ML TEZRULY NOVITIUM PHARMA N218139 July 29, 2024 DISCN SOLUTION ORAL 12427108 Feb. 1, 2041 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 9.08 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.95 WOMBAT-PK CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 9.20 WOMBAT-PK CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.93 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.88 WOMBAT-PK
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.63 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.26 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.75 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.45 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.72 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.09 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.11 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 9 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.59 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 9.16 CHEMBL

External reference:

IDSource
4019940 VUID
N0000179262 NUI
D00610 KEGG_DRUG
70024-40-7 SECONDARY_CAS_RN
63074-08-8 SECONDARY_CAS_RN
4019435 VANDF
4019940 VANDF
C0076107 UMLSCUI
CHEBI:9445 CHEBI
TZN PDB_CHEM_ID
CHEMBL611 ChEMBL_ID
CHEMBL3989562 ChEMBL_ID
DB01162 DRUGBANK_ID
CHEMBL1201091 ChEMBL_ID
C041226 MESH_SUPPLEMENTAL_RECORD_UI
5401 PUBCHEM_CID
7302 IUPHAR_LIGAND_ID
4843 INN_ID
8L5014XET7 UNII
1299927 RXNORM
31270 MMSL
36586 MMSL
44696 MMSL
5546 MMSL
d00386 MMSL
000638 NDDF
004492 NDDF
1269092006 SNOMEDCT_US
129484001 SNOMEDCT_US
387068008 SNOMEDCT_US
412519000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 10544-289 CAPSULE 10 mg ORAL ANDA 22 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-812 CAPSULE 2 mg ORAL ANDA 24 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-813 CAPSULE 5 mg ORAL ANDA 24 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-735 CAPSULE 1 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-736 CAPSULE 2 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-737 CAPSULE 5 mg ORAL ANDA 20 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 23155-738 CAPSULE 10 mg ORAL ANDA 20 sections
Terazosin Human Prescription Drug Label 1 27241-288 CAPSULE 1 mg ORAL ANDA 12 sections
Terazosin Human Prescription Drug Label 1 27241-289 CAPSULE 2 mg ORAL ANDA 12 sections
Terazosin Human Prescription Drug Label 1 27241-290 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Human Prescription Drug Label 1 27241-291 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-211 CAPSULE 1 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-212 CAPSULE 2 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-870 CAPSULE 10 mg ORAL ANDA 22 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-820 CAPSULE 1 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-821 CAPSULE 2 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-822 CAPSULE 5 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-823 CAPSULE 10 mg ORAL ANDA 26 sections
TERAZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42549-666 CAPSULE 5 mg ORAL ANDA 24 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50090-0657 CAPSULE 1 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0659 CAPSULE 10 mg ORAL ANDA 25 sections
Terazosin Human Prescription Drug Label 1 50090-1559 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1943 CAPSULE 5 mg ORAL ANDA 25 sections
Terazosin Human Prescription Drug Label 1 50090-2371 CAPSULE 10 mg ORAL ANDA 25 sections
Terazosin Human Prescription Drug Label 1 50090-2623 CAPSULE 2 mg ORAL ANDA 25 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-764 CAPSULE 1 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-765 CAPSULE 2 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-766 CAPSULE 5 mg ORAL ANDA 26 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-767 CAPSULE 10 mg ORAL ANDA 26 sections
terazosin HUMAN PRESCRIPTION DRUG LABEL 1 51655-915 CAPSULE 2 mg ORAL ANDA 20 sections